DIPK2A

Across TCGA pan-cancer cohorts, DIPK2A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DIPK2A data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DIPK2A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DIPK2A expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where DIPK2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	0.294	0.927	<.001	67	view →
HNSC	OS	Tertile	All	0.785	0.951	.020	20	view →
LUAD	OS	Quartile	II,III,IV	0.568	0.869	.036	3	view →
LSCC	DFS	Median	III,IV	0.988	0.639	.042	1	view →
GBM	OS	Median	All	0.910	0.650	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DIPK2A–CCRCC (OS)

Open the CCRCC breakdown →